Pharmacological targeting of coagulation factor XI mitigates the development of experimental atherosclerosis in low-density lipoprotein receptor-deficient mice.
atherosclerosis
contact activation
factor XI
obesity
vascular permeability
Journal
Journal of thrombosis and haemostasis : JTH
ISSN: 1538-7836
Titre abrégé: J Thromb Haemost
Pays: England
ID NLM: 101170508
Informations de publication
Date de publication:
04 2021
04 2021
Historique:
revised:
21
12
2020
received:
30
06
2020
accepted:
04
01
2021
pubmed:
10
1
2021
medline:
15
5
2021
entrez:
9
1
2021
Statut:
ppublish
Résumé
Human coagulation factor (F) XI deficiency, a defect of the contact activation system, protects against venous thrombosis, stroke, and heart attack, whereas FXII, plasma prekallikrein, or kininogen deficiencies are asymptomatic. FXI deficiency, inhibition of FXI production, activated FXI (FXIa) inhibitors, and antibodies to FXI that interfere with FXI/FXII interactions reduce experimental thrombosis and inflammation. FXI inhibitors are antithrombotic in patients, and FXI and FXII deficiencies are atheroprotective in apolipoprotein E-deficient mice. Investigate the effects of pharmacological targeting of FXI in experimental models of atherogenesis and established atherosclerosis. Low-density lipoprotein receptor-knockout (Ldlr Pharmacological targeting of FXI reduced atherogenesis in Ldlr
Sections du résumé
BACKGROUND
Human coagulation factor (F) XI deficiency, a defect of the contact activation system, protects against venous thrombosis, stroke, and heart attack, whereas FXII, plasma prekallikrein, or kininogen deficiencies are asymptomatic. FXI deficiency, inhibition of FXI production, activated FXI (FXIa) inhibitors, and antibodies to FXI that interfere with FXI/FXII interactions reduce experimental thrombosis and inflammation. FXI inhibitors are antithrombotic in patients, and FXI and FXII deficiencies are atheroprotective in apolipoprotein E-deficient mice.
OBJECTIVES
Investigate the effects of pharmacological targeting of FXI in experimental models of atherogenesis and established atherosclerosis.
METHODS AND RESULTS
Low-density lipoprotein receptor-knockout (Ldlr
CONCLUSION
Pharmacological targeting of FXI reduced atherogenesis in Ldlr
Identifiants
pubmed: 33421301
doi: 10.1111/jth.15236
pmc: PMC8549080
mid: NIHMS1748238
pii: S1538-7836(22)00719-X
doi:
Substances chimiques
Lipoproteins, LDL
0
Receptors, LDL
0
Factor XI
9013-55-2
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1001-1017Subventions
Organisme : NIH Clinical Center
ID : R01HL101972
Organisme : NIH Clinical Center
ID : R01GM116184
Organisme : NHLBI NIH HHS
ID : R01 HL101972
Pays : United States
Organisme : NIH Clinical Center
ID : R35HL140025
Organisme : NIGMS NIH HHS
ID : R01 GM116184
Pays : United States
Organisme : NHLBI NIH HHS
ID : R35 HL140025
Pays : United States
Informations de copyright
© 2021 International Society on Thrombosis and Haemostasis.
Références
N Engl J Med. 2015 Apr 23;372(17):1672
pubmed: 25901434
Arterioscler Thromb Vasc Biol. 2004 Jan;24(1):12-22
pubmed: 14604830
Blood. 2012 May 17;119(20):4762-8
pubmed: 22442348
Nucleic Acids Res. 2014 Jul;42(13):8796-807
pubmed: 24992960
Atherosclerosis. 2015 Oct;242(2):639-46
pubmed: 25817329
PLoS One. 2016 Apr 05;11(4):e0152968
pubmed: 27046148
J Intern Med. 2005 May;257(5):399-414
pubmed: 15836656
N Engl J Med. 2012 Jan 5;366(1):9-19
pubmed: 22077192
J Mol Cell Cardiol. 2019 Feb;127:1-10
pubmed: 30500376
Blood. 1997 Nov 15;90(10):3819-43
pubmed: 9354649
J Am Coll Cardiol. 2013 Jul 23;62(4):329-37
pubmed: 23665099
Cerebrovasc Dis. 2001;11 Suppl 2:1-4
pubmed: 11316915
PLoS One. 2013;8(2):e55784
pubmed: 23409043
J Gastrointest Surg. 2011 Sep;15(9):1602-10
pubmed: 21691924
Circulation. 2016 Aug 23;134(8):611-24
pubmed: 27496857
Circulation. 2018 Oct 23;138(17):1850-1863
pubmed: 29794082
Blood Adv. 2019 Feb 26;3(4):658-669
pubmed: 30808684
BMC Med. 2019 Nov 20;17(1):206
pubmed: 31744503
J Infect Dis. 2008 Jul 15;198(2):271-4
pubmed: 18491973
Arterioscler Thromb Vasc Biol. 2011 Jul;31(7):1506-16
pubmed: 21677293
Am J Clin Pathol. 2006 Sep;126(3):411-5
pubmed: 16880142
Arterioscler Thromb Vasc Biol. 2014 Aug;34(8):1668-73
pubmed: 24947525
JACC Cardiovasc Imaging. 2010 Sep;3(9):947-55
pubmed: 20846630
J Thromb Haemost. 2014 May;12(5):606-13
pubmed: 24977287
Circulation. 2010 Aug 24;122(8):821-30
pubmed: 20697022
Blood. 2010 Nov 11;116(19):3981-9
pubmed: 20634381
N Engl J Med. 2015 Jan 15;372(3):232-40
pubmed: 25482425
Pharmacol Ther. 2021 Feb;218:107676
pubmed: 32898547
Am J Pathol. 2001 Feb;158(2):469-79
pubmed: 11159184
J Pharmacol Exp Ther. 2012 Nov;343(2):253-7
pubmed: 22837011
Circ Res. 2017 Sep 1;121(6):e53-e79
pubmed: 28729353
Arterioscler Thromb Vasc Biol. 2005 Aug;25(8):e123-6
pubmed: 15920033
N Engl J Med. 1991 Jul 18;325(3):153-8
pubmed: 2052060
Circulation. 2001 Jun 26;103(25):3044-6
pubmed: 11425765
Arterioscler Thromb Vasc Biol. 2006 Dec;26(12):2787-92
pubmed: 16990551
Thromb Haemost. 2017 Jan 5;117(1):176-187
pubmed: 27786338
Thromb Res. 1994 Aug 1;75(3):329-35
pubmed: 7992244
Blood. 2009 Jul 9;114(2):452-8
pubmed: 19351955
Ann Intern Med. 2016 Jun 21;164(12):826-35
pubmed: 27064261
Nature. 2002 Dec 19-26;420(6917):868-74
pubmed: 12490960
J Am Heart Assoc. 2015 Jul 17;4(7):
pubmed: 26187996
J Thromb Haemost. 2005 Apr;3(4):695-702
pubmed: 15733058
Arterioscler Thromb Vasc Biol. 2016 Mar;36(3):475-81
pubmed: 26800563
Eur Heart J. 2004 Jul;25(14):1197-207
pubmed: 15246637
J Thromb Haemost. 2019 Sep;17(9):1449-1460
pubmed: 31125187
N Engl J Med. 2017 Oct 5;377(14):1319-1330
pubmed: 28844192
Clin Rev Allergy Immunol. 2016 Oct;51(2):152-61
pubmed: 27122021
J Pediatr. 2008 Jul;153(1):61-4
pubmed: 18571537
Sci Rep. 2019 Mar 7;9(1):3909
pubmed: 30846818